Insulet Corporation (PODD)
Insulet (PODD) Earnings Expected to Grow: Should You Buy?
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Insulet Stock a Smart Addition to Your Portfolio Right Now?
PODD continues to make strides with Omnipod 5 and its market expansion. Robust solvency is a plus.
Should You Continue to Retain PODD Stock in Your Portfolio Now?
Insulet's Omnipod 5 is set to drive growth in the upcoming quarters. Meanwhile, the stock is facing challenges due to economic uncertainties.
What Helped Insulet Stock Gain 10% This Week?
Insulet stock (NASDAQ: PODD) currently trades around $200 per share, about 35% lower than the levels of over $300 seen in early November 2021. In comparison, its peer – DexCom stock – is down 55% over this period.
Why Insulet Stock Was Zooming Higher This Week
The highly specialized medical device maker earns an important nod from a top regulator. A label expansion could potentially reach a market of 6 million people.
Insulet's Omnipod 5 Wins FDA Approval for Type 2 Diabetes
PODD marks a major milestone with Omnipod 5 approval for the treatment of type 2 diabetes.
This Healthcare Stock Is the Best Performer in the S&P 500 Tuesday
Insulet got a key FDA approval for an insulin delivery system.
These Two Stocks Plunged After Eli Lilly Drug Study Showed Diabetes Promise
Shares of Insulet (PODD) and DexCom (DXCM), two companies that provide medical devices for patients managing diabetes, tumbled Tuesday after a study showed that a popular drug made by Eli Lilly (LLY) significantly lowers the risk of developing type 2 diabetes.
Insulin Pump Maker Insulet's Stock Slumps on User Growth Concerns
Shares of Insulet (PODD) suffered the heaviest losses of any S&P 500 stock on Friday, dropping 8.8% after the maker of insulin management devices suggested new user growth could be lower than previously expected in the second half of 2024, despite topping second-quarter sales estimates.
Insulet Is the Worst Stock in S&P 500 Today, Despite Solid Earnings. Here's Why.
The automated insulin technology developer stock is on track for its largest percentage decline since February.
Insulin Pump Maker Insulet's Growth Catalysts Set to Boost Revenue in 2025: Analyst
Insulin device maker Insulet Corporation PODD reported a second-quarter adjusted EPS of $0.55 on Thursday, missing the consensus estimate of $0.56. It reported an EPS of $0.38 a year ago.
Insulet (PODD) Q2 Earnings Miss Estimates, '24 Sales View Raised
Insulet's (PODD) second-quarter performance benefits from the continued high demand for Omnipod 5.
